Insider Purchases: Inside the Buy

Tag: medical technology

Robotic spine surgery technology beside a rising ATEC stock chart, illustrating Alphatec’s insider buying and free-cash-flow turnaround.

🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴

Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?

 

Read entire article

Tags: Alphatec, Alphatec Holdings, Alphatec stock, ATEC, ATEC stock, buy or sell ATEC, CarpeDiem, contrarian investing, ContrarianInvestment, featured-insiders, free cash flow, FUNanc1al, FunStock Index, growth stocks, hub-insiders, insider buying, insider purchases, InsiderBuying, Keith Valentine, medical technology, MedTech, medtech stocks, OsteoAdapt, Pat Miles, PatMiles, Patrick Miles, risks buying ATEC, RoboticSurgery, short interest, short squeeze, ShortSqueeze, small cap stocks, spine surgery, SpineSurgery, surgical robotics, turnaround stocks, TurnAroundStock, Valence robotics, ValueInvesting, why buy ATEC
Robotic orthopedic surgical arm beside a plunging ENOV stock chart, illustrating Enovis insider buying, cheap valuation and its eCential robotics bet.

🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖

Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.

 

Read entire article

Tags: acquisition analysis, ASTRA, buy or sell ENOV, CarpeDiem, cash flow, contrarian investing, Damien McDonald, DamienMcDonald, eCential Robotics, eCentialRobotics, ENOV, ENOV stock, ENOV stock analysis, Enovis, Enovis insider buying, Enovis stock, Enovis stock analysis, falling knife, featured-insiders, forward PE, FUNanc1al, FunStock Index, FunStock Method, healthcare stocks, hub-insiders, hub-value, Inside the Buy, insider buying, insider purchases, InsiderBuying, institutional ownership, medical technology, MedTech, medtech stocks, momentum investing, orthopedic stocks, risks buying ENOV, robotics stocks, RoboticSurgery, short interest, ShortSqueeze, signal collision, stock momentum, surgical robotics, undervalued stocks, value stocks, ValueInvesting, why buy ENOV
Cinematic illustration of Boston Scientific as a futuristic medtech powerhouse, with glowing cardiovascular devices, a heart-shaped stock chart, doctors, investors, and a $2B buyback shield symbolizing healthcare innovation and a GARP stock opportunity.

🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse

Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.

Read entire article

Tags: Boston Scientific, BostonScientific, BSX, BSX stock, buy or sell BSX, cardiovascular devices, CardiovascularTech, dividend growth stocks, FARAPULSE, featured-insiders, FUNanc1al, GARP, GARP investing, growth stocks, healthcare investing, healthcare stocks, hub-insiders, insider buying, InsiderBuying, medical device stocks, medical technology, MedicalDevices, MedTech, medtech stocks, NYSE BSX, risks buying BSX, ShareRepurchase, stock buyback, stock market analysis, value investing, ValueInvesting, WATCHMAN FLX, why buy BSX